Gerresheimer AG (GXIG)

Currency in EUR
27.140
-0.640(-2.30%)
Closed·
Advertisement
GXIG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
26.92027.840
52 wk Range
14.83046.740
Key Statistics
Prev. Close
27.14
Open
27.76
Day's Range
26.92-27.84
52 wk Range
14.83-46.74
Volume
94.25K
Average Volume (3m)
207.65K
1-Year Change
-35.9029%
Book Value / Share
31.3
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GXIG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
25.264
Downside
-6.91%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Gerresheimer AG News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

2 Buy
6 Hold
3 Sell
Ratings:
11 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 25.264
(-6.91% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Deutsche Bank
Hold26.00-4.20%22.00Maintain04/08/2026
Barclays
Sell25.00-7.89%17.00Maintain30/07/2026
Barclays
Sell17.00-37.36%19.00Maintain07/07/2026
Berenberg
Hold24.00-11.57%20.00Maintain02/07/2026
Bernstein SocGen Group
Hold28.70+5.75%18.90Upgrade01/07/2026

Gerresheimer AG Earnings Call Summary for Q4/2025

  • Gerresheimer reported €2.3B revenue (+€330M YoY) but only 0.3% organic growth, with adjusted EBITDA flat at €384M and negative €86M free cash flow.
  • Shares fell 3.47% to $25.06 as investors focused on weak cash generation, high 4.95x debt leverage, and €1.65 EPS loss despite completing compliance cleanup.
  • Primary Packaging Glass segment remained under pressure from lower volumes and plant issues; syringes/medical devices grew on GLP-1 demand and new project ramps.
  • Management expects 2026 revenue at lower half of €2.3-2.4B range, EBITDA margin of 17-18%, but negative €50-100M free cash flow excluding Centor sale proceeds.
  • CEO prioritized selling Centor by November 2026 and completing debt refinancing with Lazard; transformation program expected to add €10-20M EBITDA in 2026.
Last Updated: 29/06/2026, 15:08
Read Full Transcript

Earnings

Latest Release
30/07/2026
EPS / Forecast
-0.12 / 0.41
Revenue / Forecast
499.01M / 513.95M
EPS Revisions
Last 90 days

Compare GXIG to Peers and Sector

Metrics to compare
GXIG
Peers
Sector
Relationship
P/E Ratio
−2.9x18.1x−0.4x
PEG Ratio
0.010.120.00
Price/Book
0.9x1.7x2.6x
Price / LTM Sales
0.4x1.2x3.0x
Upside (Analyst Target)
−13.6%13.8%54.3%
Fair Value Upside
Unlock11.1%8.4%Unlock

Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization, and contract manufacturing of drug delivery programs; project and quality management; and drug delivery devices, including inhalers, injection/auto injectors, and pen injectors. The company also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, it offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, samplers and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. The company offers its products to pharmacy chains, supermarkets, and wholesalers. The company serves pharma, biotech, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. Gerresheimer AG was founded in 1864 and is based in Düsseldorf, Germany.

Employees
13528
Market
Germany

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
9.72M28.14%270.04M
Other Institutional Investors
18.70M54.14%519.44M
Public Companies & Retail Investors
6.12M17.72%170.04M
Total
34.54M100.00%959.52M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
The Goldman Sachs Group, Inc.11.89%4,106,480114,078
Goldman Sachs Asset Management, L.P.8.75%3,021,12983,927

People Also Watch

75.60
DWSG
+2.02%
40.86
8TRA
-1.02%
58.450
EVDG
+0.52%
9.850
DEZG
+0.66%
115.500
TLXGn
-0.60%

FAQ

What Is the Gerresheimer AG (Xetra: GXIG) Share Price Today?

The Gerresheimer AG stock price today is 27.140 EUR.

What Stock Exchange Does Gerresheimer AG (GXIG) Trade On?

Gerresheimer AG is listed and trades on the Frankfurt Stock Exchange.

What Is the Ticker (Stock Symbol) for Gerresheimer AG?

The stock symbol (also called a 'ticker') for Gerresheimer AG is "GXIG."

What Is the Current Gerresheimer AG Market Capitalisation?

As of today, Gerresheimer AG (Xetra: GXIG) market cap is 955.030M EUR.

What Is Gerresheimer AG's (GXIG) Earnings Per Share (TTM)?

The Gerresheimer AG EPS is currently -9.274 (Trailing Twelve Months).

When Is the Next Gerresheimer AG Earnings Date?

Gerresheimer AG's next earnings report will be released on 01/10/2026.

Is GXIG a Buy or Sell From a Technical Analyst Perspective?

Based on today's Gerresheimer AG moving averages and other technical indicators, the daily buy/sell signal for GXIG stock is Strong Sell.

How Many Times Has Gerresheimer AG Stock Split?

Gerresheimer AG has split 0 times. (See the GXIG stock split history page for full effective split date and price information.)

How Many Employees Does Gerresheimer AG Have?

Gerresheimer AG has 13528 employees, based on their latest Companies House report.

What is the current trading status of Gerresheimer AG (Xetra: GXIG)?

As of 04/08/2026, Gerresheimer AG (GXIG) is trading at a share price of 27.140 EUR, with a previous close of 27.140 EUR. The stock has fluctuated within a day range of 26.920 EUR to 27.840 EUR, while its 52-week range spans from 14.830 EUR to 46.740 EUR.

What Is Gerresheimer AG (GXIG) Price Target According to Analysts?

The average 12-month price target for Gerresheimer AG is 25.264 EUR, with a high estimate of 46 EUR and a low estimate of 12.5 EUR. 2 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Neutral. The stock has an -6.91% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.